Q2 2025 results: Net sales of $534 million (+7% actual rates); adjusted diluted EPS of $0.60 Net sales +6% CER (constant exchange rates) above out...
Group sales revenue up 6.1 percent in the first six months As expected, continued positive trend in recurring business with consumables Bioproce...
Net sales increased organically by 2.5% to € 5.3 billion EBITDA pre up organically by 5.8% to € 1.5 billion All three b...
Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin...
Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic...
Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated resu...
Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of ...
CEO Paul Hudson: Confidence in Full-Year Outlook Paul Hudson, Chief Executive Officer: “We had a strong start in 2025 with sales growth of 9.7%, b...
- Recorded Q1’25 consolidated revenue of KRW 1.3 trillion - Recorded Q1’25 consolidated operating profit of KRW 486.7 billion - Company exp...
First quarter revenue was $10.36 billion. First quarter GAAP diluted earnings per share (EPS) grew 15% to $3.98. First quarter adjusted EPS gre...
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025 Revenue grew 9.6% YoY to RMB 18,675.4 million, with ...
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology treatm...
Key Financial Highlights: Full-year net sales increased to €21.2 billion (organically: +2.0%) EBITDA pre rose to €6.1 billion (orga...
Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billion Fourth Quarter 2024 Net Loss of $31.3 million, de...
© 2025 Biopharma Boardroom. All Rights Reserved.